Nootropics Index - Save on smarter supplements
Nootropics>Amino acids & derivatives>Agmatine
Amino acids & derivatives

Agmatine

agmatine sulfate / 1-(4-aminobutyl)guanidine

Agmatine is an arginine metabolite sold mainly as agmatine sulfate. It is distinct from L-arginine, and its nitric-oxide, imidazoline and NMDA-related mechanisms do not establish a healthy-user nootropic benefit. Compare the salt form, labelled amount, price per gram, GI tolerance and blood-pressure context.

GlutamatergicNitric Oxide RelatedIsolated CompoundSyntheticEndogenous CompoundLimited Human EvidenceMixed Evidence
Updated October 2026/6 min read/9 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

Agmatine is distinct from L-arginine

1

Agmatine is formed by decarboxylating arginine, but it is not interchangeable with L-arginine. Supplement labels most often use agmatine sulfate.

Evidence boundary2
Use this page to compare salt form, labelled amount, vascular context and claim quality. Healthy-user nootropic claims need more direct human evidence.

Common supplement form

2

Commercial supplements commonly list agmatine sulfate. Confirm the exact form and milligrams in the Supplement Facts panel before comparing products.

Related to arginine, not equivalent to it

5

Agmatine is an arginine metabolite. That biochemical relationship does not mean agmatine, L-arginine and citrulline have interchangeable effects or evidence.

Human evidence remains indirect for nootropic use2
Human agmatine sulfate studies provide dose and tolerability context in non-nootropic settings. They do not establish reliable focus, memory or mood effects for healthy users.
02

Names, aliases and forms

Chemical Names1-(4-aminobutyl)guanidine; (4-aminobutyl)guanidine
Salt Formagmatine sulfate
Common Namedecarboxylated arginine
Cas Number306-60-5
Pubchem Cid199
03

Mechanisms of action

Mechanisms are broad, not claim-ready

5

Agmatine is discussed in relation to imidazoline receptors, NMDA-related signaling, nitric-oxide pathways and polyamine metabolism. These mechanisms provide research context, not proof of a consumer outcome.

04

Potential effects and evidence map

Human agmatine sulfate evidence is limited and not centered on healthy cognition. Published human work provides safety and dose context in non-nootropic settings, while many brain and performance claims rely on mechanisms, animal pharmacokinetics, or preclinical research. Current evidence supports targeted cautions more than a broad moderate-risk label.

Effect domainMagnitudeGrade
Focus / attention5
UnknownConfidence: High

Reliable focus or attention enhancement is not established in healthy-user human studies.

Note Mechanistic brain-pathway interest is not a consumer focus claim.

0/5
E
Memory / learning5
UnknownConfidence: High

Direct memory enhancement is not established in healthy-user human studies.

Note Do not extrapolate from mechanisms or non-nootropic clinical settings.

0/5
E
Mood / wellbeing5
UnknownConfidence: High

Direct mood benefit is not established for healthy-user supplementation.

Note Keep public copy away from clinical-condition claims.

0/5
E
Cellular / long-term brain support5
UnknownConfidence: High

Mechanistic brain-pathway literature does not establish a long-term brain benefit for supplement users.

Note Mechanism information is presented separately from outcome evidence.

0/5
E
05

Typical dosages and timing

Typical
500-1000 mg/day
Not a recommendation
Lower bound
500 mg/day
Profile value
Upper bound
1000 mg/day
Profile value
consumer-label comparison2Profile-card context

The range shown in the profile card is a current consumer-label comparison, not a clinical target. Non-nootropic research has used gram-range regimens, which should not be copied into general supplement use.

06

Timing & effect horizon

Effect horizonUnknown
Unknown
Repeated-use study context2

Human agmatine sulfate studies used repeated daily dosing over days to months in pain-related settings. Those study courses are not a single-dose duration, a cognition timeline or a recommended cycle.

No validated human nootropic duration2

This profile does not identify a reliable human acute-onset or single-dose duration value for nootropic use. Repeated-use non-nootropic study schedules do not supply one.

Animal pharmacokinetics remain animal context9

Animal plasma and CNS pharmacokinetic findings cannot establish a human nootropic onset, duration or cycling schedule.

07

Safety, side effects and risk profile

Stacking and blood-pressure context4
Combining agmatine with citrulline, arginine, pre-workouts or other vascular products can make tolerance and perceived effects harder to attribute. The cited cardiovascular review identifies preclinical dose- and route-dependent effects; it does not establish a clinical interaction. People managing blood pressure or medicines should review supplement changes with their prescriber.
Main practical caution4
Preclinical vascular findings are a targeted evidence gap, while limited human studies do not establish a broad cardiovascular harm signal. People managing blood pressure or medicines should review supplement changes with their prescriber rather than assume a known agmatine interaction.
Safety evidence remains limited7
Available short human studies and a small longer-course case series generally reported good tolerability. These reports do not establish broad long-term safety.
Cardiovascular caution4
Confidence: Medium

Preclinical, dose- and route-dependent vascular effects support an evidence-gap caution. Clinical interaction or adverse-event risks for people using blood-pressure, nitrate or glucose-lowering medicines are not established.

Note This is a targeted evidence-gap caution, not proof of a known human interaction or a blanket high-risk label.

2/5
D
GI discomfort2
Confidence: Medium

GI discomfort, diarrhea, or nausea can occur, especially at higher gram-range intakes.

Note In dose-escalation human work, mild-to-moderate diarrhea and mild nausea appeared in the highest-dose cohort and resolved after stopping.

2/5
C
Headache / dizziness4
Confidence: Low

Headache, flushing, dizziness, or lightheadedness are plausible tolerance issues but are not a strong signal in the limited human studies.

Note Keep as a practical caution for sensitive users rather than a moderate-risk driver.

1/5
D
Evidence uncertainty5
Confidence: High

The main buyer risk is evidence overreach: healthy-user nootropic claims are much weaker than mechanistic marketing suggests.

Note This is an evidence-quality concern, not a toxicity signal.

2/5
B
Legal / regulatory risk6
Confidence: Medium

U.S. supplement claims should stay within dietary-supplement rules and avoid implying clinical care outcomes.

Note Keep regulatory copy jurisdiction-scoped.

1/5
C
GI tolerance first2GI upset, diarrhea, nausea

Human studies generally report good tolerability. Mild-to-moderate diarrhea and mild nausea appeared in the highest-dose cohort of a dose-escalation study and resolved after intake stopped.

08

Legal and regulatory status

United States, 20266

In the United States, dietary supplements are not preapproved by FDA for safety or effectiveness before sale. Claims must be truthful and substantiated, and disease claims can cause a product to be regulated as a drug.

09

Practical buying and quality notes

  • Compare agmatine sulfate milligrams, price per gram, capsule count, testing information and other vascular ingredients. Do not use mechanism language in place of human outcome evidence.1
10

FAQ

Is agmatine a nootropic?

2

Not in a strong evidence-based sense. It has interesting mechanisms, but direct healthy-user focus and memory evidence is limited.

How much agmatine is typical?

2

The range shown in the profile card is current label-comparison context. Higher gram-range regimens in non-nootropic research are not a general target.

How fast does agmatine work, and how long does it last?

2

For nootropic use, this profile does not identify a reliable human acute-onset or single-dose duration value. Repeated daily dosing in non-nootropic studies and animal pharmacokinetics are indirect context only.

Why mention blood-pressure context?

4

Agmatine intersects with nitric-oxide, imidazoline and other vascular pathways, and a preclinical review found dose- and route-dependent cardiovascular effects. That supports a targeted caution, but limited human supplement studies do not support classifying agmatine as broadly high risk.

What claims deserve caution?

5

Be cautious with memory, mood, pain, pump, neuroprotection or duration claims unless the product cites human evidence for the exact outcome, form and dose. Mechanisms and animal kinetics do not establish a human effect duration.

11

References

  1. PubChem Compound Summary for Agmatine. National Center for Biotechnology Information.
  2. Keynan O, Mirovsky Y, Dekel S, Gilad VH, Gilad GM. Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. Pain Med. 2010;11(3):356-368.
  3. Evidence for safety of the dietary ingredient agmatine sulfate as assessed by mutagenicity and genotoxicity studies. Toxicol Rep. 2024;13:101720.
  4. Exploring the Cardiovascular Impacts of Agmatine: A Systematic Review. Med Sci (Basel). 2025;13(4):255.
  5. Piletz JE, Aricioglu F, Cheng JT, et al. Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs. 2007;21(11):885-900.
  6. U.S. Food and Drug Administration. Dietary Supplements.
  7. Rosenberg ML, Tohidi V, Sherwood K, et al. Evidence for Dietary Agmatine Sulfate Effectiveness in Neuropathies Associated with Painful Small Fiber Neuropathy. Nutrients. 2020;12(2):576.
  8. Gilad GM, Gilad VH. Long-term (5 years), high daily dosage of dietary agmatine--evidence of safety: a case report. J Med Food. 2014;17(11):1256-1259.
  9. Clements BM, Peterson CD, Kitto KF, Caye LD, Wilcox GL, Fairbanks CA. Biodistribution of Agmatine to Brain and Spinal Cord after Systemic Delivery. J Pharmacol Exp Ther. 2023;387(3):328-336.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.